# Postoperative Monacolin K Supplementation and Lipid Profile After Sleeve Gastrectomy: A Retrospective Comparative Analysis in Women

**Authors:** Krzysztof Nocoń, Urszula Kukla, Daria Gendosz de Carrillo, Claudia Wawrzynosek, Halina Jędrzejowska-Szypułka, Dominika Krakowczyk, Aleksander J. Owczarek, Kamila Szeliga, Tomasz Sawczyn

PMC · DOI: 10.3390/nu18040647 · Nutrients · 2026-02-16

## TL;DR

This study found that early post-surgery monacolin K supplementation in women who had sleeve gastrectomy improved lipid profiles compared to controls.

## Contribution

The novel finding is that early monacolin K supplementation stabilizes LDL cholesterol and enhances lipid optimization after sleeve gastrectomy.

## Key findings

- Early monacolin K supplementation reduced LDL-C and triglycerides more effectively than controls.
- Delayed supplementation showed partial improvements in triglycerides and HDL-C.
- Supplementation did not interfere with weight loss benefits after surgery.

## Abstract

Background: Sleeve gastrectomy (SG) reliably reduces weight and triglycerides, but LDL-C responses are variable. In this retrospective observational study, we evaluated whether adjunctive monacolin K (red yeast rice; 3 mg/day) improves early lipid modulation after SG. Methods: In this single-center retrospective study of women only, 149 patients undergoing SG within the national KOS-BAR program were analyzed in four groups: controls without supplementation (CG, n = 62) and three supplementation cohorts receiving monacolin K for 6 months (G1 early (from week 1; n = 46), G2 delayed (months 3–9; n = 10), and G3 delayed (months 6–12; n = 31)). Outcomes included total cholesterol (TC), LDL-C, HDL, and triglycerides (TG). Missing data were imputed; mixed models for repeated measures assessed longitudinal changes. Results: From baseline to 6 months, LDL-C-C increased in the control group (CG; +21.9 mg/dL) and decreased in G1 (mean change: −11.1 mg/dL), with a significant group-by-time interaction (p < 0.001). HDL-C increased in both CG and G1, whereas triglyceride levels decreased more markedly in G1 than in CG (−36.2 vs. −19.6 mg/dL). Total cholesterol decreased in G1 (−13.4 mg/dL) and in G2 at 9 months (−22.5 mg/dL). Conclusions: In the early supplementation group, LDL-C-C levels decreased over the first 6 months after SG, whereas an increase was observed in the control group, which had significantly lower baseline LDL-C concentrations. In women undergoing SG, early postoperative monacolin K supplementation was associated with LDL-C stabilization and enhanced lipid optimization without impeding weight-loss benefits. Delayed initiation yields partial improvements, especially for TG and HDL-C. These observations underscore the need for prospective, sex-stratified studies with appropriate baseline adjustments to clarify the association between monacolin K use and postoperative lipid trajectories after SG.

## Linked entities

- **Chemicals:** monacolin K (PubChem CID 53232)

## Full-text entities

- **Genes:** APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}
- **Diseases:** mass (MESH:C536030), Morbid Obesity (MESH:D009767), liver dysfunction (MESH:D017093), myopathy (MESH:D009135), hypercholesterolemia (MESH:D006937), Obesity (MESH:D009765), obstructive sleep apnea (MESH:D020181), T2DM (MESH:D003924), chronic kidney disease (MESH:D051436), excess weight loss (MESH:D015431), BO (MESH:D010149), KOS (MESH:C537013), hypertension (MESH:D006973), hypothyroidism (MESH:D007037), dyslipidemia (MESH:D050171), injury to (MESH:D014947)
- **Chemicals:** glucose (MESH:D005947), Cholesterol (MESH:D002784), alcohol (MESH:D000438), citrinin (MESH:D002953), Lipid (MESH:D008055), methylene blue (MESH:D008751), Monacolin K (MESH:D008148), carbohydrates (MESH:D002241), TG (MESH:D014280), sitosterol (MESH:C025473), desmosterol (MESH:D003897), zinc (MESH:D015032), cholestanol (MESH:D004083), campesterol (MESH:C021273), lathosterol (MESH:C001521), fat (MESH:D005223), LDL-C (-)
- **Species:** Oryza sativa (Asian cultivated rice, species) [taxon 4530], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943251/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943251/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943251/full.md

---
Source: https://tomesphere.com/paper/PMC12943251